Raised Guidance Altering The Investment Case For Eli Lilly Stock?
FROM THE WIRE · FINANCE.YAHOO.COM
Eli Lilly reported Q3 2026 sales of US$24.4b and net income of US$6.5b, raised full-year revenue guidance to a range of US$91b to US$92b, and released clinical data across obesity, diabetes, and oncology programs. Beyond headline incretin demand, Lilly is tying higher revenue…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA mega-cap pharma raising full-year revenue guidance is a material event for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly reported Q3 2026 sales of $24.4 billion.
- 02Net income for the quarter was $6.5 billion.
- 03Full-year revenue guidance was raised to $91-92 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets